Recent Publications

List of most recent publications led by the Sant Pau Memory Unit:

  1. Early Motor Changes in Genetic Frontotemporal Dementia. Lleó, A, Illán-Gala, I Neurology 2022
    PMID:36219793

  2. Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease. Benejam, B, Aranha, MR, Videla, L et al. Alzheimers Res Ther 2022
    PMID:36057615

  3. Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma. Valle-Tamayo, N, Pérez-González, R, Chiva-Blanch, G et al. J Vis Exp 2022
    PMID:35993755

  4. Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome. Videla, L, Benejam, B, Pegueroles, J et al. JAMA Netw Open 2022
    PMID:35930282

  5. Myelin loss in C9orf72 hexanucleotide expansion carriers. Sirisi, S, Querol-Vilaseca, M, Dols-Icardo, O et al. J Neurosci Res 2022
    PMID:35766328

  6. Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. Iulita, MF, Garzón Chavez, D, Klitgaard Christensen, M et al. JAMA Netw Open 2022
    PMID:35604690

  7. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. Illán-Gala, I, Nigro, S, VandeVrede, L et al. JAMA Netw Open 2022
    PMID:35486397

  8. Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease. Aranha, MR, Fortea, J, Carmona-Iragui, M et al. Neurology 2022
    PMID:35470138

  9. Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications. Altuna, M, Olmedo-Saura, G, Carmona-Iragui, M et al. Int J Mol Sci 2022
    PMID:35457126

  10. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Cervantes González, A, Irwin, DJ, Alcolea, D et al. Mol Neurodegener 2022
    PMID:35395770

  11. Fluid markers of synapse degeneration in synucleinopathies. Cervantes González, A, Belbin, O J Neural Transm (Vienna) 2022
    PMID:35147800

  12. Cortical microstructure in primary progressive aphasia: a multicenter study. Illán-Gala, I, Montal, V, Borrego-Écija, S et al. Alzheimers Res Ther 2022
    PMID:35139897

  13. Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Reyes-Leiva, D, Dols-Icardo, O, Sirisi, S et al. Front Neurol 2021
    PMID:35115992

  14. The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone. Delaby, C, Estellés, T, Zhu, N et al. Alzheimers Res Ther 2022
    PMID:35105351

  15. [Preliminary study of the temporal variables of continuous speech in patients with neurodegenerative syndromes of the frontotemporal lobar degeneration spectrum]. Baqué, L, Machuca, MJ, Santos-Santos, MA et al. Rev Neurol 2022
    PMID:35014018

  16. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Zhu, N, Santos-Santos, M, Illán-Gala, I et al. Transl Neurodegener 2021
    PMID:34893073

  17. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Querol-Vilaseca, M, Sirisi, S, Molina-Porcel, L et al. Neuropathol Appl Neurobiol 2022
    PMID:34825396

  18. Alzheimer's disease associated with Down syndrome: a genetic form of dementia. Fortea, J, Zaman, SH, Hartley, S et al. Lancet Neurol 2021
    PMID:34687637

  19. The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery : NGF Pathway Biomarkers and Drug Targets. Pentz, R, Iulita, MF Adv Exp Med Biol 2021
    PMID:34453291

  20. Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. Montal, V, Barroeta, I, Bejanin, A et al. Ann Neurol 2021
    PMID:34309066

  21. Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Carmona-Iragui, M, Alcolea, D, Barroeta, I et al. Lancet Neurol 2021
    PMID:34302785

  22. Sleep Disorders in Adults with Down Syndrome. Giménez, S, Altuna, M, Blessing, E et al. J Clin Med 2021
    PMID:34300177

  23. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Lleó, A, Zetterberg, H, Pegueroles, J et al. Nat Commun 2021
    PMID:34262030

  24. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. Bejanin, A, Iulita, MF, Vilaplana, E et al. JAMA Neurol 2021
    PMID:34228042

  25. Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity. Altuna, M, Giménez, S, Fortea, J et al. J Clin Med 2021
    PMID:34202784

  26. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. Lleó, A, Carmona-Iragui, M, Videla, L et al. Alzheimers Res Ther 2021
    PMID:34183050

  27. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Alcolea, D, Delaby, C, Muñoz, L et al. J Neurol Neurosurg Psychiatry 2021
    PMID:34103344

  28. Biomarkers in neurological disorders: a fast-growing market. Lleó, A Brain Commun 2021
    PMID:33977270

  29. AMYQ: An index to standardize quantitative amyloid load across PET tracers. Pegueroles, J, Montal, V, Bejanin, A et al. Alzheimers Dement 2021
    PMID:33797846

  30. Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. Illán-Gala, I, Falgàs, N, Friedberg, A et al. JAMA Netw Open 2021
    PMID:33704477

Search PubMed